Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call at the 59th European Renal Association (ERA) Congress
- Data on atrasentan to be presented in an oral presentation from the IgA nephropathy (IgAN) patient cohort of the phase 2 AFFINITY basket trial
- Updated data to be presented from Cohort 1 of Part 3 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN
- Additional abstracts to be presented include atrasentan’s mechanism to block mesangial cell injury and the pathogenic transcriptional networks driving IgAN progression in a translational model, as well as a systems nephrology framework for the molecular classification of chronic kidney disease to fuel
Chinook's precision medicine strategy through the Evotec collaboration Chinook to host investor conference call and webcast onMay 20, 2022 to review and discuss presented abstracts
Abstract Title: | Atrasentan for the Treatment of IgA Nephropathy: Interim Results from the AFFINITY Study |
Presenting Author: | Muh Geot Wong, Ph.D., |
Session Title: | Recent advances in the treatment of IgAN |
Session Time: | |
Abstract Title: | A Systems Nephrology Framework for the Molecular Classification of Chronic Kidney Disease |
Presenting Author: | Tobias Bohnenpoll, Ph.D., Evotec SE |
Session Title: | Classification of chronic kidney disease |
Session Time: | |
Mini-oral Presentations:
Abstract Title: | Updated Interim Results of a Phase 1/2 Study to Investigate the Safety, Tolerability, |
Pharmacokinetics, Pharmacodynamics and Clinical Activity of BION-1301 in Patients with IgA | |
Nephropathy | |
Presenting Author: | |
Session Title: | Glomerulonephritis |
Session Time: | |
Abstract Title: | Selective Endothelin A Receptor Antagonist Atrasentan Attenuates Mesangial Cell Injury, |
Proteinuria and Intra-Renal Proliferative, Inflammatory and Fibrotic Transcriptional Networks | |
in a |
|
Presenting Author: | |
Session Title: | Glomerulonephritis |
Session Time: | |
Abstract Title: | A Phase 1/2, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and |
Pharmacodynamics of BION-1301 in |
|
Presenting Author: | |
Session Title: | Glomerulonephritis |
Session Time: | |
For more information on these and other abstracts, please visit the 59th ERA
Investor Conference Call Details
To access the call, please dial (844) 309-0604 (domestic) or (574) 990-9932 (international) and provide the Conference ID 9428716 to the operator.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcast will remain available for replay on Chinook’s website for 90 days.
About
Cautionary Note on Forward-Looking Statements
Certain of the statements made in this press release are forward looking, including those relating to Chinook’s business, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding the advancement of its products and the timing of initiation and results of clinical trials. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, including initiation of clinical trials of our existing product candidates or those developed as part of the Evotec collaboration, whether results of early clinical trials or preclinical studies will be indicative of the results of future trials, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that may be more advanced or have greater resources than we do, our ability to obtain and adequately protect intellectual property rights for our product candidates and the effects of COVID-19 on our clinical programs and business operations. Many of these risks are described in greater detail in our filings with the
Contact:Noopur Liffick Vice President, Investor Relations & Corporate Communications investors@chinooktx.com media@chinooktx.com
Source: Chinook Therapeutics, Inc.